- Flat profit forecast
- Big increase in non-cash impairments
It has been a fraught year for Alliance Pharma (APH) and its shareholders. First there were multiple delays to the publication of its annual results to allow auditors more time with the accounts (never an encouraging sign). Then it was revealed last month that chief executive Peter Butterfield would be leaving the group “to pursue other business interests”.